文献速递瓣膜病与结构性心脏病

经导管主动脉瓣置换术后脑微出血的前瞻性MRI队列研究

Cerebral Microbleeds During Transcatheter Aortic Valve Replacement: A Prospective Magnetic Resonance Imaging Cohort.
PubMed 文献 · Circulation · 2022-06-20

该前瞻性队列纳入84例接受TAVR的症状性主动脉瓣狭窄患者,术前26%存在脑微出血,术后23%出现新发脑微出血。新发脑微出血与手术时间延长及术后获得性血管性血友病因子缺陷独立相关,但与6个月神经功能结局无关。

要点

  • TAVR术前约1/4患者存在脑微出血,术后约1/4出现新发脑微出血。
  • 手术时间延长和术后获得性vWF缺陷与新发脑微出血独立相关。
  • 新发脑微出血未影响6个月神经功能结局或生活质量。

核心结论

  • 接受TAVR的患者中,1/4术前存在脑微出血,1/4术后出现新发脑微出血。
  • 手术或抗血栓管理及持续性获得性血管性血友病因子缺陷与新发脑微出血相关。

研究设计与样本

  • 前瞻性队列研究(METHYSTROKE),纳入84例因症状性主动脉瓣狭窄接受TAVR的患者。
  • 术前术后行标准化神经评估、脑MRI及止血指标(包括血管性血友病因子)分析。
  • 由两名独立且盲法的神经放射科医生报告微出血数目和位置。

主要发现

  • 术前MRI显示22例(26% [95% CI, 17%-37%])至少存在1个微出血。
  • 术后19例(23% [95% CI, 14%-33%])出现新发微出血。
  • 新发微出血与基线微出血及DWI高信号无关。
  • 单因素分析中,既往出血史(P=0.01)、较高肝素总剂量(P=0.02)、手术时间延长(P=0.03)、未使用鱼精蛋白逆转(P=0.04)、较高最终APTT(P=0.05)、较低最终vWF高分子量多聚体比值(P=0.007)及较低最终ADP闭合时间(P=0.02)与新发微出血相关。
  • 多因素分析中,手术时间延长(每5分钟透视时间OR 1.22 [95% CI, 1.03-1.73],P=0.02)和术后获得性vWF缺陷(高分子量多聚体比值每降低0.1单位OR 1.42 [95% CI, 1.08-1.89],P=0.004)独立相关。

临床怎么用

  • TAVR围术期应关注脑微出血风险,尤其对于手术时间较长或存在获得性vWF缺陷的患者。
  • 优化抗血栓管理(如肝素剂量、鱼精蛋白逆转)可能有助于减少新发脑微出血,但需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cerebral microbleeds (CMBs) have been observed in healthy elderly people undergoing systematic brain magnetic resonance imaging. The potential role of acute triggers on the appearance of CMBs remains unknown. We aimed to describe the incidence of new CMBs after transcatheter aortic valve replacement (TAVR) and to identify clinical and procedural factors associated with new CMBs including hemostatic measures and anticoagulation management. METHODS: We evaluated a prospective cohort of patients with symptomatic aortic stenosis referred for TAVR for CMBs (METHYSTROKE [Identification of Epigenetic Risk Factors for Ischemic Complication During the TAVR Procedure in the Elderly]). Standardized neurologic assessment, brain magnetic resonance imaging, and analysis of hemostatic measures including von Willebrand factor were performed before and after TAVR. Numbers and location of microbleeds on preprocedural magnetic resonance imaging and of new microbleeds on postprocedural magnetic resonance imaging were reported by 2 independent neuroradiologists blinded to clinical data. Measures associated with new microbleeds and postprocedural outcome including neurologic functional outcome at 6 months were also examined. RESULTS: A total of 84 patients (47% men, 80.9±5.7 years of age) were included. On preprocedural magnetic resonance imaging, 22 patients (26% [95% CI, 17%-37%]) had at least 1 microbleed. After TAVR, new microbleeds were observed in 19 (23% [95% CI, 14%-33%]) patients. The occurrence of new microbleeds was independent of the presence of microbleeds at baseline and of diffusion-weighted imaging hypersignals. In univariable analysis, a previous history of bleeding (P=0.01), a higher total dose of heparin (P=0.02), a prolonged procedure (P=0.03), absence of protamine reversion (P=0.04), higher final activated partial thromboplastin time (P=0.05), lower final von Willebrand factor high-molecular-weight:multimer ratio (P=0.007), and lower final closure time with adenosine-diphosphate (P=0.02) were associated with the occurrence of new postprocedural microbleeds. In multivariable analysis, a prolonged procedure (odds ratio, 1.22 [95% CI, 1.03-1.73] for every 5 minutes of fluoroscopy time; P=0.02) and postprocedural acquired von Willebrand factor defect (odds ratio, 1.42 [95% CI, 1.08-1.89] for every lower 0.1 unit of high-molecular-weight:multimer ratio; P=0.004) were independently associated with the occurrence of new postprocedural microbleeds. New CMBs were not associated with changes in neurologic functional outcome or quality of life at 6 months. CONCLUSIONS: One out of 4 patients undergoing TAVR has CMBs before the procedure and 1 out of 4 patients develops new CMBs. Procedural or antithrombotic management and persistence of acquired von Willebrand factor defect were associated with the occurrence of new CMBs. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT02972008.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Van Belle E, Debry N, Vincent F, et al. Cerebral Microbleeds During Transcatheter Aortic Valve Replacement: A Prospective Magnetic Resonance Imaging Cohort. Circulation. 2022. PMID: 35722876. doi:10.1161/CIRCULATIONAHA.121.057145

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。